Abstract
Liver metastasis is a frequent and serious complication of pancreatic cancer, contributing to its high mortality rate. Identifying risk factors and understanding the timing of liver metastasis may improve early detection and support more effective treatment planning. A cohort of 12,955 incident pancreatic cancer patients was assembled from the Truveta platform. A subgroup of cases and controls that met the inclusion/exclusion criteria was analyzed using logistic regression and was reported as the primary analysis for this study. Effects on time to liver metastasis were also analyzed using univariate and multivariate Cox regression models. The primary outcome was the occurrence of liver metastasis within 1 year of diagnosis. Subjects were categorized as having baseline metastasis (≤ 30 days from pancreatic cancer diagnosis) or post-baseline metastasis (>30 days). Demographic characteristics and comorbidities were evaluated for their potential role as risk factors. Among 7,858 patients in the case-control cohort, 2,920 (37%) developed liver metastasis within one year, while 2,066 (70%) subjects were diagnosed with metastasis at baseline. Male sex, older age, and a history of Type 2 diabetes mellitus, depression, obesity, anemia, abdominal pain, and distant metastasis were significantly associated with a higher risk of liver metastasis. Lower odds of liver metastasis were observed among Black or African American and Hispanic or Latino subjects. In the subgroup analysis after removing baseline metastasis, surgery and radiotherapy were protective, while tumors located in the head of the pancreas showed a higher risk for metastasis in this cohort. Interestingly, pancreatic head tumors were less likely to metastasize in the full cohort.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research is supported by the NIH R01GM134307, R01GM145700 and the MSU SPG grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data available : No As a result of contractual agreements with TRUVETA, we are unable to export individual patient data. It is possible for researchers to gain access to individual patient data, but they must enter into an agreement with TRUVETA and pay a fee in order to do so. The data used in this study is available to all Truveta subscribers and may be accessed at studio.truveta.com.
